These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

705 related articles for article (PubMed ID: 22069160)

  • 21. Prognostic value of biomarkers related to drug resistance in patients with advanced epithelial ovarian cancer.
    Kim H; Kim K; No JH; Jeon YT; Jeon HW; Kim YB
    Anticancer Res; 2012 Feb; 32(2):589-94. PubMed ID: 22287749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).
    Seifert H; Georgiou A; Alexander H; McLachlan J; Bodla S; Kaye S; Barton D; Nobbenhuis M; Gore M; Banerjee S
    Gynecol Oncol; 2015 Nov; 139(2):216-20. PubMed ID: 26318078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer.
    Rauh-Hain JA; Foley OW; Winograd D; Andrade C; Clark RM; Vargas RJ; Hinchcliff EM; Esselen KM; Horowitz NS; del Carmen MG
    Am J Obstet Gynecol; 2015 May; 212(5):600.e1-8. PubMed ID: 25514761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition.
    Parikh A; Lee C; Joseph P; Marchini S; Baccarini A; Kolev V; Romualdi C; Fruscio R; Shah H; Wang F; Mullokandov G; Fishman D; D'Incalci M; Rahaman J; Kalir T; Redline RW; Brown BD; Narla G; DiFeo A
    Nat Commun; 2014; 5():2977. PubMed ID: 24394555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression.
    Tang W; Jiang Y; Mu X; Xu L; Cheng W; Wang X
    Cell Signal; 2014 Jul; 26(7):1420-6. PubMed ID: 24607788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Weekly dose-dense paclitaxel and carboplatin in recurrent ovarian carcinoma: a phase II trial.
    Shawky H; Tawfik H; Hewidy M
    J Egypt Natl Canc Inst; 2014 Sep; 26(3):139-45. PubMed ID: 25150129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA-150 predicts a favorable prognosis in patients with epithelial ovarian cancer, and inhibits cell invasion and metastasis by suppressing transcriptional repressor ZEB1.
    Jin M; Yang Z; Ye W; Xu H; Hua X
    PLoS One; 2014; 9(8):e103965. PubMed ID: 25090005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of the mitotic-arrest deficiency 2 is associated with chemotherapy resistance in ovarian serous adenocarcinoma.
    Nakano Y; Sumi T; Teramae M; Morishita M; Fukuda T; Terada H; Yoshida H; Matsumoto Y; Yasui T; Ishiko O
    Oncol Rep; 2012 Oct; 28(4):1200-4. PubMed ID: 22797604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
    Katsumata N; Yasuda M; Isonishi S; Takahashi F; Michimae H; Kimura E; Aoki D; Jobo T; Kodama S; Terauchi F; Sugiyama T; Ochiai K;
    Lancet Oncol; 2013 Sep; 14(10):1020-6. PubMed ID: 23948349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: a single institution experience.
    Bamias A; Karadimou A; Soupos N; Sotiropoulou M; Zagouri F; Haidopoulos D; Thomakos N; Rodolakis A; Antsaklis A; Dimopoulos MA
    Gynecol Oncol; 2011 Oct; 123(1):37-42. PubMed ID: 21764430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
    Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
    Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas.
    Niu N; Shen W; Zhong Y; Bast RC; Jazaeri A; Sood AK; Liu J
    Hum Pathol; 2021 Jul; 113():20-27. PubMed ID: 33887301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas.
    Johnatty SE; Beesley J; Gao B; Chen X; Lu Y; Law MH; Henderson MJ; Russell AJ; Hedditch EL; Emmanuel C; Fereday S; Webb PM; ; Goode EL; Vierkant RA; Fridley BL; Cunningham JM; Fasching PA; Beckmann MW; Ekici AB; Hogdall E; Kjaer SK; Jensen A; Hogdall C; Brown R; Paul J; Lambrechts S; Despierre E; Vergote I; Lester J; Karlan BY; Heitz F; du Bois A; Harter P; Schwaab I; Bean Y; Pejovic T; Levine DA; Goodman MT; Camey ME; Thompson PJ; Lurie G; Shildkraut J; Berchuck A; Terry KL; Cramer DW; Norris MD; Haber M; MacGregor S; deFazio A; Chenevix-Trench G
    Gynecol Oncol; 2013 Oct; 131(1):8-14. PubMed ID: 23917080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers.
    Sereni MI; Baldelli E; Gambara G; Ravaggi A; Hodge KA; Alberts DS; Guillen-Rodriguez JM; Dong T; Memo M; Odicino F; Angioli R; Liotta LA; Pecorelli SL; Petricoin EF; Pierobon M
    Br J Cancer; 2017 Aug; 117(4):494-502. PubMed ID: 28664915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women.
    Crim A; Rowland M; Ruskin R; Dvorak J; Greenwade M; Walter A; Gillen J; Ding K; Moore K; Gunderson C
    Gynecol Oncol; 2017 Aug; 146(2):268-272. PubMed ID: 28583323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression.
    Zhang J; Liu L; Sun Y; Xiang J; Zhou D; Wang L; Xu H; Yang X; Du N; Zhang M; Yan Q; Xi X
    Oncotarget; 2016 May; 7(18):26516-34. PubMed ID: 27049921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
    Jean S; Li J; Katsaros D; Wubbenhorst B; Maxwell KN; Fishbein L; McLane MW; Benedetto C; Canuto EM; Mitra N; Zhang L; Nathanson KL; Tanyi JL
    Oncotarget; 2016 Jul; 7(30):48577-48585. PubMed ID: 27191893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study.
    Rubatt JM; Darcy KM; Tian C; Muggia F; Dhir R; Armstrong DK; Bookman MA; Niedernhofer LJ; Deloia J; Birrer M; Krivak TC
    Gynecol Oncol; 2012 May; 125(2):421-6. PubMed ID: 22261301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.